Ovid Therapeutics Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $7.3M | $566,000 | $392,000 | $1.5M | $208.4M |
| Operating income | -$42.4M | -$61.9M | -$59.3M | -$55.5M | $124.2M |
| Operating expenses | $49.7M | $62.5M | $59.7M | $57.1M | $84.2M |
| Cash from operations | -$38.3M | -$56.0M | -$45.8M | -$55.2M | $118.6M |
| Capital expenditure | $0 | $71,000 | $40,000 | $1.2M | $184,008 |
| Free cash flow | -$38.3M | -$56.0M | -$45.8M | -$56.5M | $118.4M |
| Total assets | $150.9M | $92.2M | $144.0M | $155.3M | $194.5M |
| Total liabilities | $20.3M | $23.9M | $56.2M | $23.0M | $14.8M |
Shares outstanding 186.6M · Free float 83.9%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.